

1 **Supplementary information**

2 **Materials and Methods**

3 **TCGA data**

4 Gene expression data (normalized count of RNA-seq data) and DNA methylation data
5 (β value of methylation array data) of head and neck squamous cell carcinoma in TCGA
6 (TCGA-HNSC) were downloaded from the TCGA website
7 (<https://cancergenome.nih.gov/>). Pearson correlation analysis was applied to calculate
8 the correlation between gene expression and DNA methylation data.

9 **Patient samples**

10 Patients with OSCC were recruited from the Department of Oral and Maxillofacial
11 Surgery, Kaohsiung Medical University Hospital. They were independently diagnosed
12 by two dental pathologists, and the diagnoses were confirmed using clinical and
13 histological data. Each patient's clinical cancer [TNM (tumor–node–metastasis)] stage
14 was determined according to the 1992 criteria of the American Joint Cancer
15 Committee/Union International Cancer Control (AJCC/UICC) ⁸. Overall survival (OS)
16 was defined as the interval between the date of diagnosis and death. Disease-free
17 survival (DFS) was defined as the interval from the date of diagnosis and date of first
18 recurrence, locoregional or systemic. All other events were censored. IRB approval and
19 informed consent from patients were obtained (KMUH-IRB-20130300).

20 **Tissue microarray and immunohistochemical analysis**

21 To determine the immunohistochemical expression of MRE11 in OSCC, FFPE
22 (formalin-fixed, paraffin-embedded) tumor tissues were examined in a tissue
23 microarray. Slides from hematoxylin-eosin-stained sections were reviewed by a
24 specialist pathologist to select representative areas of tumor and normal tissues for core
25 biopsy within the primary paraffin blocks. Tissue microarray was constructed following
26 standard tissue array-producing protocols ⁵. Four-micrometer sections were cut from
27 recipient tissue microarray blocks by an adhesive-coated tape sectioning microtome
28 (Alphelys). Immunohistochemical analysis was performed using an automatic IHC-
29 staining device, according to the manufacturer's instructions (Bond-max Automated
30 Immunostainer; Vision Biosystems, Melbourne, Australia) ¹. Goat anti-human MRE11
31 polyclonal antibody (dilution 1:200) was purchased from Santa Cruz Biotechnology
32 (Santa Cruz, CA), and the same antibody was also used for immunoblotting. Images of
33 immunohistochemically stained sections were captured by Nikon E600 microscope
34 (Nikon, Tokyo, Japan), and processed with Adobe Photoshop 6.0 (Adobe System
35 Incorporated, San Jose, CA). Only nuclear staining of MRE11 was counted.
36 The percentage of positively-stained tumor cells was determined semiquantitatively by
37 assessing tumor sections, with each sample assigned to one of the following categories:
38 0 (0-4%), 1 (5-24%), 2 (25-49%), 3 (50-74%), or 4 (75-100%). Additionally, intensity

39 of immunostaining was determined as 0 (negative), 1 (weak), 2 (moderate) or 3 (strong).
40 The total score was designated as the percentage of positively-stained cells multiplied
41 by the weighted intensity of staining for each sample. For further statistical analysis,
42 scores ≤ 9 were categorized as low expression, and >9 were categorized as high
43 expression (cut point at median). The staining was determined separately for each
44 specimen by two independent experts simultaneously under the same conditions ^{2,7}.

45 **Oncomine™ platform**

46 Oncomine™ , an integrated cancer microarray database and web-based data-mining
47 platform ⁶, was used to search for genes that may be correlated with MRE11.

48 **Cell culture**

49 Human oral squamous cancer cell lines Ca9-22, CAL 27, HSC-3, OEC-M1 and LN1-
50 1, a subline of OEC-M1 isolated from a metastatic cervical lymph node ⁹, were obtained
51 and authenticated (genotype and phenotype authentication) by the Bioresource
52 Collection and Research Center, Taiwan (www.bcrc.firdi.org.tw). All media were
53 purchased from Thermo Fisher Scientific (Waltham, MA, USA) and supplemented with
54 10% (vol/vol) fetal bovine serum (FBS) (Biological Industries, Haemek, Israel) and
55 antibiotics (100 units/mL penicillin, 100 μ g/mL streptomycin, and 2.5 μ g/mL
56 amphotericin B) (Biological Industries, Haemek, Israel). All cells were grown and

57 maintained at 37°C in a 5% CO₂ incubator (Thermo Fisher Scientific, Waltham, MA,
58 USA). Cells were regularly tested for mycoplasma contamination.

59 **Virus infection for MRE11 knockdown/overexpression**

60 MRE11 was silenced in oral squamous cell carcinoma cells with a lentivirus carrying a
61 pLKO.1_puro lentiviral vector expressing double-stranded shRNA oligonucleotides
62 targeting the sequence of human MRE11 (shRNA1, 5'-
63 GCTGCGTATTAAAGGGAGGAA-3', National RNAi Core Facility, Academia Sinica,
64 Taiwan). Another pLKO.1_puro lentiviral vector expressing shRNA targeting firefly
65 luciferase, unrelated to the human genome sequence, was used as negative control
66 (National RNAi Core Facility, Academia Sinica, Taiwan).

67 For overexpression of MRE11 in OSCC cells, ready-to-use lentiviral particles
68 containing pReceiver Lv105 lentiviral vector which expressed human MRE11 gene
69 were purchased from Genecopoeia (Rockville, MD). For negative control, lentiviral
70 particles which carried an empty pReceiver Lv105 lentiviral vector were used
71 (Genecopoeia, Rockville, MD). Lentiviral infection was performed by adding viral
72 solution to cells, with culture media containing 8 µg/mL polybrene. After infection for
73 48 hrs, 2µg/mL puromycin was added for selection. Surviving cells were maintained
74 continuously with 2µg/mL puromycin and cultured for further experiments.

75 **XTT cell proliferation assay**

76 XTT (tetrazolium salt 2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-
77 carboxanilide) assay was performed to evaluate the effect of MRE11 on OSCC cell
78 proliferation. HSC-3 and OECM1 cells with MRE11 knockdown and Ca9-22 and CAL
79 27 cells with MRE11 overexpression were seeded (2×10^3 cells per well) in 96-well
80 culture plates. At time points of 24hr, 48hr and 72hr after seeding, the medium was
81 removed, and 150 μ L of XTT solution (50 μ g XTT and 0.4 μ g PMS in 150 μ L of culture
82 media) (Sigma-Aldrich, St. Louis, MO) was added and incubated at 37°C for 2hr. The
83 assay was performed by measuring optical density (OD) at 475 nm and subtracting
84 nonspecific background at 660 nm ($OD_{475nm} - OD_{660nm}$).

85 **Immunoblotting analysis**

86 Immunoblotting was performed as described previously ¹⁰. The chemiluminescent
87 signal was captured by Gel Doc™ XR+ Gel Documentation System (BIO-RAD,
88 Hercules, CA). The following antibodies were used: goat anti-human MRE11 (sc-5859,
89 Santa Cruz, CA), rabbit anti-human γ -H2AX (GTX61796, GeneTex, Irvine, CA), rabbit
90 anti-human p-Akt Ser473 (#3787, Cell signaling, Danvers, MA), rabbit anti-human p-
91 Erk (GTX61126, GeneTex, Irvine, CA), rabbit anti-human Akt (#4691, Cell signaling,
92 Danvers, MA), rabbit anti-human Erk (GTX82556, GeneTex, Irvine, CA), rabbit anti-
93 human p-STAT3 (GTX61050, GeneTex, Irvine, CA), rabbit anti-human STAT3
94 (GTX15523, GeneTex, Irvine, CA), rabbit anti-human ZO-1 (GTX108613, GeneTex,

95 Irvine, CA), rabbit anti-human E-cadherin (GTX100443, GeneTex, Irvine, CA), rabbit
96 anti-human twist (GTX127310, GeneTex, Irvine, CA), rabbit anti-human vimentin
97 (GTX100619, GeneTex, Irvine, CA), rabbit anti-human β -catenin (ab16051, Abcam,
98 Cambridge, UK), mouse anti-human CD44, rabbit anti-human CXCR-4 (sc-9046,
99 Santa Cruz, CA), rabbit anti-human FOXA2 (ab108422, Abcam, Cambridge, UK),
100 rabbit anti-human Lamin A/C (GTX62457, GeneTex, Irvine, CA), rabbit anti-human
101 GAPDH (GTX100118, GeneTex, Irvine, CA), rabbit anti-human α -tubulin
102 (GTX112141, GeneTex, Irvine, CA), and mouse anti-human β -actin (A5441, Sigma-
103 Aldrich, St. Louis, MO). HRP-conjugated goat anti-rabbit and anti-mouse antibodies
104 were obtained from GeneTex (Irvin, CA).

105 **In vitro migration and invasion assays**

106 Cell migration assay was carried out using Transwell (Corning Costar Corp.,
107 Cambridge, MA, USA) membrane filter inserts in 24-well tissue culture plates (6.5mm
108 diameter, 8 μ m pore size). For invasion assay, Transwell inserts were coated with
109 Matrigel on the upper side. After overexpression or knockdown of MRE11, oral cancer
110 cells were trypsinized and suspended in serum-free medium, and seeded on the upper
111 chamber of transwell filters. Serum-containing medium was added to the lower
112 chamber and incubated for 24hrs at 37°C. The cells were then fixed with 4%
113 formaldehyde, and stained with crystal violet. Non-migrating cells were removed by

114 wiping the upper side of the filter. The number of migrated cells was determined by
115 Image J software.

116 **Annexin V staining**

117 FITC Annexin V Apoptosis Detection Kit I (BD Biosciences, San Jose, CA) was used
118 to detect apoptotic cells during apoptosis progression after radiation or CDDP treatment.
119 HSC-3 cells with MRE11 knockdown or Ca9-22 and CAL 27 cells with MRE11
120 overexpression were seeded on 6cm plates. At time points of 24hr and 48hr after
121 radiation or CDDP treatment, 1×10^6 cells were collected and washed twice with ice-
122 cold phosphate-buffered saline (PBS; 137 mM NaCl, 2.7 mM KCl, 10 mM Na₂HPO₄,
123 and 2 mM KH₂PO₄ [pH=7.4]). The cells were then stained with Annexin V working
124 solution (5 μ L of Annexin V-FITC reagent and 5 μ L of propidium iodide (PI) solution in
125 100 μ L of 1X Annexin V binding buffer) for 15 minutes at room temperature.
126 Subsequent analysis was performed with Cytomics FC 500 flow cytometer (Beckman
127 Coulter, Brea, CA, USA). The fluorescence signals of Annexin V-FITC and PI were
128 detected by FL-1 and FL-3 channels respectively, and 10,000 cells were analyzed in 3
129 independent experiments.

130 **TUNEL staining**

131 APO-DIRECT™ Kit (BD Biosciences, San Jose, CA) was used to detect late apoptotic
132 cells after radiation treatment. HSC-3 cells with MRE11 knockdown or Ca9-22 and

133 CAL 27 cells with MRE11 overexpression were seeded on 6cm plates. At time points
134 of 24hr and 48hr after radiation treatment, 1×10^6 cells were collected and fixed with
135 fix solution (1% formaldehyde in 70% ethanol) for 24hrs at -20°C . The following
136 procedures were performed according to the manufacturer's instructions. Subsequent
137 analysis was performed with Cytomics FC 500 flow cytometer (Beckman Coulter, Brea,
138 CA, USA). The fluorescence signals of FITC-dUTP and PI were detected by FL-1 and
139 FL-3 channels respectively, and 10,000 cells were analyzed in 3 independent
140 experiments.

141 **Ionizing radiation treatment of OSCC cells**

142 HSC-3 cells with MRE11 knockdown or Ca9-22 and CAL 27 cells with MRE11
143 overexpression were irradiated at doses of 2, 5 and 10 Gy at room temperature using a
144 6MV linear accelerator (ELEKTA-Sli, Norcross, GA, USA) at the Department of
145 Radiation Oncology, KMU Hospital. The cells were then obtained for further
146 experiments.

147 **γ -H2AX activation after IR exposure**

148 HSC-3 cells with MRE11 knockdown or Ca9-22 and CAL 27 cells with MRE11
149 overexpression were grown on 6cm plates. After 10 Gy γ -irradiation, the medium was
150 removed and the cells were collected for further protein extraction.

151 **Neutral comet assay**

152 Neutral comet single-cell gel electrophoresis was used for determining irradiation-
153 induced DSBs in HSC-3 cells with MRE11 knockdown or Ca9-22 and CAL 27 cells
154 with MRE11 overexpression. Cells were grown on 6cm-plates and after 10 Gy IR
155 exposure, cells were collected at time points of 24, 48 and 72hr for further comet assay.
156 According to the manufacturer's protocol (Trevigen, Gaithersburg, MD), collected cells
157 (10,000 cells) were mixed with 50 μ L of low-melting point agarose gel and placed on a
158 comet slide (Trevigen, Gaithersburg, MD), followed by electrophoresis at 21 volts for
159 20 min in neutral electrophoresis buffer. The slide was washed with ddH₂O for 5 min,
160 DNA was stained with propidium iodide (PI) solution for 5min, followed by a further
161 wash with ddH₂O for 5 min. Comet tails produced by DNA damage in individual cells
162 were visualized with fluorescence microscopy and further quantified with Image J
163 software. Tail moments [(tail mean – head mean) \times (% tail DNA/100)] were
164 automatically calculated by software. Three independent experiments were performed
165 and more than 50 individual cells were quantified per data point.

166 **Colony forming assay**

167 HSC-3 cells with MRE11 knockdown or Ca9-22 and CAL 27 cells with MRE11
168 overexpression were seeded in 6-well plates (1,000 cells/well), exposed to 2, 5, 10 Gy
169 irradiation and incubated at 37°C for 14 days. The cells were then washed twice with

170 PBS and stained with 0.1% crystal violet for 15 minutes before counting. Clusters
171 including at least 50 cells were counted as colonies. Three independent experiments
172 were performed.

173 **Antibody neutralization**

174 To elucidate signal transduction pathways involving CXCR4 and Akt, Ca9-22 and CAL
175 27 cells with MRE11 overexpression were treated with CXCR4 ligand SDF-1
176 (500ng/mL) or CXCR4 neutralization antibody (5µg/mL) and incubated at 37°C for 48
177 hrs. The cell lysate was collected and protein level was analyzed by immunoblotting
178 method.

179 **Inhibition of MRE11 nuclease activity**

180 The effects of MRE11 nuclease activity on cell survival and mobility were analyzed by
181 MRE11 nuclease inhibitor mirin in Ca9-22 and CAL 27 cells with MRE11
182 overexpression at concentrations of 12.5 and 25µM for 24hrs. The cells were collected
183 for further migration assay, and protein level analyzed by immunoblotting method.
184 MRE11 H129N mutant, a nuclease-deficient form of MRE11³, was constructed and
185 infected into oral cancer cells according to the subsection of “Virus infection for
186 MRE11 knockdown/overexpression” in the Methods section.

187 **Microarray data collection and gene expression analyses**

188 Total RNA from control and MRE11-knockdowned cells was isolated with the RNeasy
189 Mini kit. Synthesis of cRNA from total RNA and hybridization/scanning of microarrays
190 were performed with Affymetrix GeneChip products (HGU133A) as described in the
191 GeneChip manual. Normalization of the raw gene expression data, quality control
192 checks, and subsequent analyses were performed with the open source R-project
193 statistical (<http://www.r-project.org/>) and Bioconductor packages. After RMA
194 normalization, the t statistic was used to generate a ranked list of differentially
195 expressed genes. GSEA and IPA pathway analyses were performed with this preranked
196 list.

197 **RT² profiler PCR array**

198 RNA from samples was extracted with the RNeasy Microkit (Qiagen). Reverse
199 transcription and realtime PCR were performed with proprietary kits and reagents from
200 Qiagen according to the manufacturer's instructions. 84 key genes from human stem
201 cell signaling PCR array (Qiagen; #PAHS-047Z) or Human Epithelial to Mesenchymal
202 Transition (EMT) PCR array (Qiagen; #PAHS-090Z) were simultaneously assayed
203 with the RT2 Profiler PCR array plate (Qiagen).

204 **In vivo oral cancer cell invasiveness in zebrafish**

205 According to the 3Rs, we minimized the number of animals used in our experiments.
206 Experiments involving zebrafish were approved by the Institutional Animal Care and

207 Use Committee of Kaohsiung Medical University (IACUC Approval No: 107023).
208 Zebrafish were randomized into several groups. Embryos of zebrafish (strain
209 *fli1:EGFP* from the Taiwan Zebrafish Core Facility; <http://tzcf-hdmrc.org/>) were
210 generated by natural pairwise mating and the xenograft procedure was based on
211 previous reports ⁴. In brief, oral cancer cells with overexpressed or knockdowned
212 MRE11 expression were labeled with fluorescent probe DiI (Life Technologies, Grand
213 Island, NY, USA), and implanted into the perivitelline cavity of 2-day-old zebrafish
214 embryos through microinjection. After confirmation of the localized DiI-labeled cell
215 mass at the injection site, the zebrafish embryos were transferred to fresh water and
216 maintained at 32.5°C for 48 h, and cell invasion was determined by visualizing
217 dissemination of the DiI-labeled cells from the injection site under Nikon Eclipse Ti-S
218 microscope (Tokyo, Japan).

219 **In vivo orthotopic tumor growth and distant metastasis in mice**

220 According to the 3Rs, we minimized the number of animals used in our experiments.
221 Six-week-old male SCID(NOD.CB17-*Prkdc*^{scid}/JNarl) mice were obtained from the
222 National Laboratory Animal Center of Taiwan (<http://www.nlac.org.tw/>), with approval
223 of all experiments by the Institutional Animal Care and Use Committee of Kaohsiung
224 Medical University (IACUC Approval No: 106094). Mice were randomized into
225 several groups.

226 For orthotopic tumor model, oral cancer cells (5×10^5 cells) resuspended in 100 μ L of
227 normal saline were injected into mice through an intrabuccal route. After six weeks, all
228 mice were sacrificed and orthotopic tumors collected for tumor weight measurement
229 and immunohistochemical analysis.

230 For distant (lung) metastasis in SCID mice, oral cancer cells (2.5×10^5 cells) with
231 luciferase expression were injected intravenously through tail vein, and distant (lung)
232 metastasis was checked by an *In vivo* imaging system (IVIS) as described below. To
233 explore the treatment strategies for MRE11-overexpressing oral cancers *in vivo*, oral
234 cancer cells CAL 27 (2.5×10^5 cells) were injected intravenously through tail vein,
235 followed by intravenous injection of CXCR4 neutralizing antibody or mouse IgG (1 μ g
236 antibody per 1g body weight). CXCR4 neutralizing antibody or mouse IgG were
237 injected twice a week for 6 weeks. All mice were euthanized six weeks later and lungs
238 collected for H&E staining and metastasis analysis. The distant (lung) metastasis was
239 analyzed by calculating H&E staining results.

240 ***In vivo* imaging system (IVIS)**

241 Six-week old male immunodeficient mice were purchased from National Laboratory
242 Animal Center (NLAC, Taiwan) and injected with 2.5×10^5 MRE11OE/Luc cells
243 suspended in 100 μ L PBS via tail vein. Cancer metastasis was monitored using IVIS-
244 50 optical imaging system (PerkinElmer) after 150 mg/kg luciferin injection

245 periodically. Before sacrifice, the mice were injected with luciferin, and mice organs
246 were collected for IVIS and histology analyses.

247 **Statistical analysis**

248 The estimated odds ratio (OR) was used to summarize the relationship between MRE11
249 expression and clinicopathological features of patients. The Cox proportional hazard
250 model was used to evaluate the association between clinicopathologic factors and
251 survival for multivariate analysis. In the multivariate analysis, variables showing *p*
252 values of less than 0.05 in the univariate analysis were included as covariates. The OS
253 and DFS were calculated using the Kaplan-Meier method, and survival curves were
254 compared by log-rank test. Two-sided Student t test was used for in vitro and in vivo
255 studies. All statistical analyses were performed using JMP version 10.0.1 for Windows
256 (SAS Institute, Cary, NC, USA) and *p* values less than 0.05 were considered statistically
257 significant.

258

259 **References**

- 260 1 Chen LC, Chung IC, Hsueh C, Tsang NM, Chi LM, Liang Y *et al.* The
261 antiapoptotic protein, FLIP, is regulated by heterogeneous nuclear
262 ribonucleoprotein K and correlates with poor overall survival of nasopharyngeal
263 carcinoma patients. *Cell death and differentiation* 2010; 17: 1463-1473.
264
- 265 2 Chuang FH, Hsue SS, Wu CW, Chen YK. Immunohistochemical expression of
266 RANKL, RANK, and OPG in human oral squamous cell carcinoma. *Journal of*
267 *oral pathology & medicine : official publication of the International Association*

- 268 of Oral Pathologists and the American Academy of Oral Pathology 2009; 38:
269 753-758.
270
- 271 3 Hoa NN, Shimizu T, Zhou ZW, Wang ZQ, Deshpande RA, Paull TT *et al.* Mre11
272 Is Essential for the Removal of Lethal Topoisomerase 2 Covalent Cleavage
273 Complexes. *Molecular cell* 2016; 64: 580-592.
274
- 275 4 Lee SL, Rouhi P, Dahl Jensen L, Zhang D, Ji H, Hauptmann G *et al.* Hypoxia-
276 induced pathological angiogenesis mediates tumor cell dissemination, invasion,
277 and metastasis in a zebrafish tumor model. *Proceedings of the National*
278 *Academy of Sciences of the United States of America* 2009; 106: 19485-19490.
279
- 280 5 Lee YC, Yang YH, Su JH, Chang HL, Hou MF, Yuan SS. High visfatin
281 expression in breast cancer tissue is associated with poor survival. *Cancer*
282 *epidemiology, biomarkers & prevention : a publication of the American*
283 *Association for Cancer Research, cosponsored by the American Society of*
284 *Preventive Oncology* 2011; 20: 1892-1901.
285
- 286 6 Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D *et al.*
287 ONCOMINE: a cancer microarray database and integrated data-mining
288 platform. *Neoplasia (New York, NY)* 2004; 6: 1-6.
289
- 290 7 Sarbia M, Stahl M, Fink U, Willers R, Seeber S, Gabbert HE. Expression of
291 apoptosis-regulating proteins and outcome of esophageal cancer patients treated
292 by combined therapy modalities. *Clinical cancer research : an official journal of*
293 *the American Association for Cancer Research* 1998; 4: 2991-2997.
294
- 295 8 Verschuur HP, Irish JC, O'Sullivan B, Goh C, Gullane PJ, Pintilie M. A matched
296 control study of treatment outcome in young patients with squamous cell
297 carcinoma of the head and neck. *The Laryngoscope* 1999; 109: 249-258.
298
- 299 9 Wang SH, Chang JS, Hsiao JR, Yen YC, Jiang SS, Liu SH *et al.* Tumour cell-
300 derived WNT5B modulates in vitro lymphangiogenesis via induction of partial
301 endothelial-mesenchymal transition of lymphatic endothelial cells. *Oncogene*
302 2017; 36: 1503-1515.
303
- 304 10 Yuan SS, Hou MF, Hsieh YC, Huang CY, Lee YC, Chen YJ *et al.* Role of
305 MRE11 in cell proliferation, tumor invasion, and DNA repair in breast cancer.

307

308

309 **Supplementary data**

310 **Figure S1. MRE11 expression and oral cancer cell behavior. (A)** Transwell

311 migration ability in various oral cancer cell lines at 24 hrs and 48 hrs. **(B)** MRE11

312 protein expression in OEC-M1 oral cancer cells after infection with different lentiviral

313 knockdown constructs, as determined by immunoblotting. **(C)** MRE11 mRNA

314 expression in HSC-3 oral cancer cells after infection with clone 1 lentiviral knockdown

315 construct, as determined by qRT-PCR. **(D)** MRE11 protein expression in oral cancer

316 cells after lentiviral knockdown and overexpression, as determined by immunoblotting.

317 **(E)** Decreased oral cancer cell viability after MRE11 knockdown, as determined by

318 XTT cell viability assay. **(F)** The expression of p-AKT and p-ERK was decreased after

319 MRE11 knockdown in oral cancer cells. **(G)** Decreased oral cancer cell colony

320 formation after MRE11 knockdown. **(H)** The dosage effect of mirin on CAL 27 oral

321 cancer cell death after treatment for 72 hours

322 **Figure S2.** The effect of MRE11 knockdown and overexpression on colony formation

323 in oral cancer cells 7 days after ionizing radiation exposure.

324 **Figure S3. The effect of MRE11 expression on chemoresistance. (A)** The effect of

325 MRE11 knockdown on oral cancer cell viability, as determined by XTT cell viability

326 assay after CDDP treatment. **(B)** The effect of MRE11 knockdown on comet tail
327 formation, an indicator for DSBs, in oral cancer cells after CDDP treatment. **(C)** The
328 effect of MRE11 knockdown on γ H2AX expression, an indicator for DSBs, in oral
329 cancer cells after CDDP treatment. **(D)** The effect of MRE11 knockdown on oral cancer
330 cell apoptosis, as determined by TUNEL positivity, after CDDP treatment. **(E)** The
331 effect of MRE11 knockdown on oral cancer cell apoptosis, as determined by Annexin
332 V positivity, after CDDP treatment. **(F)** The effect of MRE11 expression, determined
333 by IHC, on overall survival of oral cancer patients after chemotherapy.

334

335 **Figure S4. CXCR4 mRNA expression in MRE11-overexpressing oral cancer cells.**

336 **(A)** The evaluation of tumor metastasis-associated gene expression profiles in MRE11-
337 overexpressing oral cancer cells was carried out using RT² Profiler PCR Array– Human
338 Tumor Metastasis (SABioscience). **(B)** CXCR4 mRNA expression in MRE11-
339 overexpressing cells without or with CXCR4 silencing.

340

341 **Figure S5. MRE11 regulates the expression of FOXA2 and E-cadherin. (A)** In

342 MRE11-knockdowned oral cancer cells, FOXA2 moved to the nucleus. **(B)** A negative
343 correlation between MRE11 and E-cadherin expression in oral cancer tissues, as
344 determined by IHC. **(C)** A positive correlation between FOXA2 and E-cadherin

345 expression in oral cancer tissues. **(D)** Correlation between MRE11, CXCR4 and
346 FOXA2 expression using microarray datasets for oral cancer retrieved from
347 ONCOMINE Cancer Profiling Database (<https://www.oncomine.org>).

348

349 **Figure S6. The effect of MRE11 knockdown on LN1-1 oral cancer cell viability**
350 **and tumor growth. (A)** The effect of MRE11 knockdown on the viability of LN1-1
351 cells. **(B)** The effect of MRE11 knockdown on transwell migration of LN1-1 cells. **(C)**
352 The effect of MRE11 knockdown on total flux in LN1-1 orthotopic mouse model. **(D)**
353 The effect of MRE11 knockdown on tumor volume in LN1-1 orthotopic mouse model.

354

355 **Figure S7. Decreased expression of mesenchymal marker vimentin (A) and**
356 **increased expression of epithelial marker E-cadherin (B) in the MRE11-**
357 **knockdowned orthotopic mouse tumor model.**

358

359 **Figure S8. The effect of MRE11 expression in oral cancer cells on the expression**
360 **of *p*-STAT3.**

361

362 **Figure S9. Correlation of MRE11 expression with expression of replication stress**
363 **markers (A) γ H2AX, (B) *p*-ATM and (C) *p*-ATR in oral cancer tissues, as**

364 **determined by immunohistochemistry analysis.** The relationship between MRE11
365 expression and γ H2AX, *p*-ATM and *p*-ATR expression in oral cancer tissues was
366 examined using linear regression analysis.